Endocrinology Research
Diabetes & Metabolism • Osteoporosis • Thyroid Disorders
Hyperlipidemia • Obesity • Insulin Delivery & Devices
Current Enrollment Opportunities
The Sanofi “Main Meal” study: EFC 11261
This Research study is also designed for Type 2 Diabetics not achieving
their targeted Hemoglobin A1C values, but only taking Metformin. In this
study, qualifying participants will take the Investigational drug, Lixisenatide
in addition to their current dose of Metformin to see if it can better
control their blood sugar. Although this dose will be administered just
once a day, the timing of this dose may be associated either with their
main meal of the day or prior to breakfast. This study lasts a total of
28 weeks, and also has a small study with in the main study looking at
the effects of the medication using Continuous Glucose Monitoring.
Find out more about this trial
here
The Sanofi Aventis “Elixa” study: EFC11319
In this Research study, we are specifically looking for Type 2 Diabetics
who have recently suffered from an Acute Coronary Syndrome (ACS) event.
This study too involves the administration of the Investigational drug,
Lixisenatide, to determine if it can help minimize future cardiac events
by better controlling glucose levels in affected Type 2 Diabetics.
Find out more about this trial
here.